BioSpace News Archive

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, presented updated results from the ongoing Phase II SUMMIT trial of neratinib at the 2020 Virtual San Antonio Breast Cancer Symposium (SABCS) that is currently taking place.

LabCorp (NYSE: LH), a leading global life sciences company that is focused on advancing health and guiding patient care decisions, today announced that the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) for the Pixel by LabCorp™ COVID-19 Test Home Collection Kit to become the first to be available over the counter without requiring a prescription

Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced updates on the clinical development of the company’s novel Bcl-2 inhibitor APG-2575, further demonstrating the drug candidate’s therapeutic potential.

Biogen and Eisai, Co., Ltd. announced that Biogen has submitted a Japanese New Drug Application to the Ministry of Health, Labor and Welfare for aducanumab, an investigational therapy for Alzheimer’s disease.

On December 9, 2020, Kintor Pharmaceutical Limited is pleased to announce that the Group has collected positive data in phase II clinical trials of combination therapy of ALK-1 antibody and PD-1 antibody for the second line therapy of advanced hepatocellular carcinoma in Taiwan.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the launch of its Racial Equity Community Impact Fund, which will support high-impact organizations working to tackle racial inequities affecting Black communities across the United States

Dermatology Times® Welcomes Six Inductees to the 2020 Giants of Dermatology ™ Class The peer-to-peer nomination program honors physicians and industry leaders who continue to inspire, inform and advance the quality of life of patients with skin conditions and diseases.

ams (SIX: AMS), a leading worldwide supplier of high performance sensor solutions, and Senova, a manufacturer of in-vitro diagnostic medical devices based in Germany, announce yesterday that they have successfully opened a production line for lateral flow tests which will be used to detect antibodies from the Covid-19 (SARS-CoV-2) virus

Cyclo Therapeutics, Inc. (“Cyclo Therapeutics” or the “Company”) (NasdaqCM: CYTH) (NasdaqCM:CYTHW), a clinical stage biotechnology company developing a cyclodextrin platform for the treatment of Neurodegenerative Diseases, including their lead candidate (Trappsol® Cyclo™) in the treatment of Niemann-Pick Disease Type C (NPC),

The New York Genome Center announced that it has created a Scientific Advisory Board to provide counsel and support for the organization’s scientific mission.